Health Care Equipment

DexCom

Decang Medical CLO Michael Jon Brown Sells 1,700 Shares at $59.91 per Share

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

ViCentra Launches Its New Kaleido Insulin Delivery Patch Pump System Commercially

Decon Medical to Hold Investor Day Event

DexCom released FY2026 Q1 earnings on April 30 After-Market (EST), actual revenue USD 1.192 B (forecast USD 1.175 B), actual EPS USD 0.51 (forecast USD 0.4528)

DexCom Expected to Report Strong Q1 Earnings

DexCom to Release FY2026 Q1 Earnings on April 30 After-Market EST, Forecast Revenue USD 1.175 B, EPS USD 0.4575

Dexcom to Present New Clinical Evidence for Continuous Glucose Monitoring Technology at Conference

Neuberger Berman Group LLC Increased Holdings in DexCom in Q3

Jeffrey Analyst Maintains BUY Rating for Dexcom

DexCom released FY2025 earnings on February 12 After-Market (EST), actual revenue USD 4.662 B (forecast USD 4.655 B), actual EPS USD 2.0895 (forecast USD 2.0702)

DexCom released FY2025 Q4 earnings on February 12 After-Market (EST), actual revenue USD 1.26 B (forecast USD 1.254 B), actual EPS USD 0.68 (forecast USD 0.6542)

Decon Medical Q4 Earnings Beat Estimates

Thrivent Financial for Lutherans Increased Holdings in DexCom, Inc. in Q3

DexCom to release FY2025 Q4 earnings on February 12 After-Market EST, forecast revenue USD 1.254 B, EPS USD 0.6326

Expected Analysis of Dekang Medical's Q4 2025 Financial Report

DexCom Inc. forecasts 2026 revenue of $5.16 billion to $5.25 billion

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

DexCom EVP, Chief Legal Officer Michael Jon Brown sells 1,700 shares for $101,847

DXCM

Michael Jon Brown, EVP and Chief Legal Officer of DexCom, sold 1,700 shares at $59.91 each on May 15, 2026, totaling $101,847. After the sale, he retains 109,504 shares.

PUBT

SBIO

Bank of America has lowered its price target for DexCom (NASDAQ:DXCM) from $100.00 to $80.00 while maintaining a 'buy' rating. Other analysts have also adjusted their targets, with Citigroup setting a target of $79.00 and TD Cowen at $75.00. DexCom's stock is currently trading at $64.28, with a potential upside of 24.46% from the new target. The company reported earnings of $0.56 per share, exceeding estimates, and has a market cap of $24.80 billion.

Market Beat

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Bank of America

Citigroup

Mizuho Financial

Mizuho Financial Group, Inc.

Raymond James Financial

Evercore

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Bank of America Lowers DexCom (NASDAQ:DXCM) Price Target to $80.00

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany | DXCM Stock News

StockTitan

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany | DXCM Stock News

Barclays analyst Matt Miksic has maintained a Sell rating on Dexcom (DXCM) as of May 15, with a price target of $64.00. Dexcom's shares closed at $61.63. Miksic, a 2-star analyst, has an average return of 0.6% and a 47.60% success rate. The consensus on Dexcom is a Strong Buy, with an average price target of $79.94.

Tip Ranks

Barclays

Johnson & Johnson

Becton Dickinson and

Boston Scientific

Barclays Sticks to Its Sell Rating for Dexcom (DXCM)

DexCom (NASDAQ:DXCM) outlined its long-term strategy at the 2026 Investor Day, focusing on new product launches, expanded insurance coverage for continuous glucose monitoring (CGM), and international growth. CEO Jake Leach highlighted the recent G7 15 Day product launch and the upcoming G8 platform, which promises improved accuracy and connectivity. The company anticipates significant growth, with plans to double U.S. coverage by 2027 and expand internationally, while leveraging clinical data to enhance CGM access.

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

ALMS

SPRY

AARD

Healthcare stocks declined on Friday, with the NYSE Healthcare Index down 0.9%. Aardvark Therapeutics shares plummeted 31% after a clinical hold by the FDA. DexCom's shares rose over 6% following new long-term financial goals. ARS Pharmaceuticals and Alumis saw declines of nearly 5% and over 5%, respectively, due to wider losses and significant revenue drops.

Fidelity

Alumis

ARS Pharmaceuticals

Aardvark Therapeutics

iShares Global Healthcare

Health Care Select Sector SPDR

iShares US Pharma

VG Health

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Sector Update: Healthcare Stocks Softer Friday Afternoon

DexCom(DXCM.US)

DexCom EVP, Chief Legal Officer Michael Jon Brown sells 1,700 shares for $101,847

Bank of America Lowers DexCom (NASDAQ:DXCM) Price Target to $80.00

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany | DXCM Stock News

Barclays Sticks to Its Sell Rating for Dexcom (DXCM)

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

Sector Update: Healthcare Stocks Softer Friday Afternoon

Trending